Improving Resilience and Equity in Colorectal Cancer Screening: Lessons from COVID-19 and Beyond
Agenda
November 2, 2020
|
1:00-1:10 |
Agenda Review and Administrative Statements President’s Cancer Panel introduction, administrative remarks, agenda review |
|
1:10 – 2:00 |
Introductions and Working Group Work to Date Working Group and Stakeholder Panel introductions, planning process overview, and review of Working Group work to date |
|
2:00 – 3:00 |
Colorectal Cancer Screening Improvement Opportunities Session 1: Greater Promotion of FIT Opportunities to improve screening, associated barriers, and possible solutions
|
|
3:00 – 3:15 |
Break |
|
3:15 – 4:15 |
Colorectal Cancer Screening Improvement Opportunities Session 2: Greater Access to Colonoscopy and Discussion of Options Opportunities to improve screening, associated barriers, and possible solutions |
|
4:15 – 4:35 |
Working Group Review of Input and Final Comments Review of the day’s stakeholder input and reactions to day’s work |
|
4:35 – 5:00 |
Response to Public Questions and Comments |
November 4, 2020
|
1:00-1:15 |
Agenda Review and Administrative Statements Administrative remarks, facilitator introduces agenda and process, reflections from day 1 |
|
1:15 – 2:15 |
Colorectal Cancer Screening Improvement Opportunities Session 3: Guidelines (Lower Age for Discussing CRC to Age 45) Opportunities to improve screening, associated barriers, and possible solutions |
|
2:15 – 3:15 |
Colorectal Cancer Screening Improvement Opportunities Session 4: Risk Based Approach to Screening and Management Opportunities to improve screening, associated barriers, and possible solutions |
|
3:15 – 3:30 |
Break |
|
3:30 – 4:30 |
Colorectal Cancer Screening Improvement Opportunities Session 5: Improved Follow-Up, Management, and Treatment if Pathology is Found Opportunities to improve screening, associated barriers, and possible solutions |
|
4:30 – 4:40 |
Working Group Review of Input and Final Comments Brief review of input and panel discussion of next steps |
|
4:40 – 5:00 |
Response to Public Questions and Comments |